NCT00558571View on ClinicalTrials.gov

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2008

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 10773 low dose

DRUG

placebo to BI 10773

DRUG

BI 10773 medium dose

DRUG

BI 10773 high dose

Trial Locations (3)

Unknown

1245.4.49003 Boehringer Ingelheim Investigational Site, Berlin

1245.4.49002 Boehringer Ingelheim Investigational Site, Mainz

1245.4.49001 Boehringer Ingelheim Investigational Site, Neuss

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY